Related Experiment Video
Updated: May 2, 2026
07:02
Animal Model of Implant-Associated Infections in Mice
Published on: June 27, 2025
1.2K
An experimental model for Staphylococcus aureus hepatic abscess in Bama minipig
R G Zhang1, X D Wang1, X L Zhang1
1Department of Gastroenterology and Hepatology, Chinese PLA General Hospital, Beijing, China.
Genetics and Molecular Research : GMR
|March 18, 2014
Summary
This study establishes a minipig model for pyogenic hepatic abscess (PHA) using Staphylococcus aureus. This model successfully created abscesses, providing a foundation for testing new PHA treatments.
Area of Science:
- Veterinary Medicine
- Infectious Diseases
- Surgical Pathology
Background:
- Pyogenic hepatic abscess (PHA) is a severe condition requiring effective treatments.
- Current research lacks adequate animal models for studying PHA.
- The minipig model has not been extensively explored for PHA research.
Purpose of the Study:
- To develop and validate a minipig model for inducing pyogenic hepatic abscesses.
- To establish a baseline for future research on PHA treatment strategies.
- To identify the specific bacterial strain responsible for abscess formation in the model.
Main Methods:
- Induction of pyogenic hepatic abscesses in minipigs.
- Isolation and identification of causative bacterial pathogens.
- Establishment of a linear regression equation for Staphylococcus aureus ATCC 25923.
- Observation of abscess development over a 21-day period.
Main Results:
- Successful induction of pyogenic hepatic abscesses in the minipig model.
- Staphylococcus aureus ATCC 29213 identified as the sole pathogenic bacterium.
- Abscess formation was consistently observed by the 21st day post-induction.
- A linear regression equation for Staphylococcus aureus ATCC 25923 was successfully established.
Conclusions:
- The developed minipig model is suitable for studying pyogenic hepatic abscesses.
- This model provides a crucial experimental platform for evaluating novel PHA therapies.
- Further research can build upon this validated model for advancing PHA treatment.
